Patients’ characteristics according to the RADAI-5 disease activity categories (medians and ranges).
| Remission-like | RADAI-5 Categories | |||
|---|---|---|---|---|
| Mild | Moderate | High | ||
| N assessments (in n patients) | 182 (114) | 234 (167) | 223 (167) | 119 (87) |
| Interval of assessments if repeated, mo | 3 (1–10) | 3 (1–11) | 3 (1–9) | 2 (1–12) |
| Female, % | 78.3 | 79.8 | 83.2 | 87.4 |
| Age, yrs | 62 (32–84) | 61 (20–87) | 64 (23–86) | 58 (23–81) |
| Disease duration, mo | 90 (1–545) | 52 (3–519) | 56 (2–472) | 48 (3–360) |
| RF-positive, % | 64.2 | 64.2 | 56.1 | 53.3 |
| SJC* | 0 (0–14) | 1 (0–12) | 2 (0–14) | 2 (0–17) |
| TJC* | 0 (0–8) | 1 (0–9) | 2 (0–28) | 5 (0–28) |
| ESR* | 14 (2–75) | 15 (2–90) | 17 (2–84) | 21 (2–99) |
| MDGLOB* | 0.2 (0–6.0) | 1.0 (0.0–7.5) | 1.5 (0.0–7.0) | 2.0 (0.0–10.0) |
| DAS28* | 2.39 (0.49–5.11) | 3.07 (0.49–5.62) | 3.83 (0.88–5.96) | 4.65 (1.33–8.09) |
| CDAI* | 2.8 (0.0–20.5) | 6.5 (0.0–25.4) | 10.2 (1.1–35.4) | 16.5 (0.5–62.1) |
| PATSAT* | 1 (1–4) | 2 (1–5) | 3 (1–5) | 4 (1–5) |
For abbreviations, see Table 1.
↵* p < 0.001, Kruskal-Wallis test.